Evidence map›Paper›PMID 40002813›Full record

ReviewBiomedicines2025

Retinopathy of Prematurity and MicroRNAs.

Giuseppe Maria Albanese, Giacomo Visioli, Ludovico Alisi, Marta Armentano, Francesca Giovannetti, Luca Lucchino, Marco Marenco, Paola Pontecorvi, Magda Gharbiya

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomedicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Giuseppe Maria AlbaneseDepartment of Sense Organs, Sapienza-University of Rome, Viale del Policlinico 155, 00161 Rome, Italy.ORCID 0000-0001-7562-9274
Giacomo VisioliDepartment of Sense Organs, Sapienza-University of Rome, Viale del Policlinico 155, 00161 Rome, Italy.ORCID 0000-0002-6152-433X
Ludovico AlisiDepartment of Sense Organs, Sapienza-University of Rome, Viale del Policlinico 155, 00161 Rome, Italy.ORCID 0000-0001-5366-882X
Marta ArmentanoDepartment of Sense Organs, Sapienza-University of Rome, Viale del Policlinico 155, 00161 Rome, Italy.
Francesca GiovannettiDepartment of Sense Organs, Sapienza-University of Rome, Viale del Policlinico 155, 00161 Rome, Italy.ORCID 0000-0002-7661-6675
Luca LucchinoDepartment of Sense Organs, Sapienza-University of Rome, Viale del Policlinico 155, 00161 Rome, Italy.
Marco MarencoDepartment of Sense Organs, Sapienza-University of Rome, Viale del Policlinico 155, 00161 Rome, Italy.ORCID 0000-0002-6978-3790
Paola PontecorviDepartment of Experimental Medicine, Sapienza-University of Rome, Viale del Policlinico 155, 00161 Rome, Italy.ORCID 0000-0003-2392-3775
Magda GharbiyaDepartment of Sense Organs, Sapienza-University of Rome, Viale del Policlinico 155, 00161 Rome, Italy.ORCID 0000-0002-4991-9689

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Retinopathy of Prematurity (ROP), a leading cause of blindness in preterm infants, arises from dysregulated angiogenesis and inflammation. Without timely intervention, ROP can progress to severe outcomes, including dense fibrovascular plaques and retinal detachment. MicroRNAs (miRNAs) regulate key pathways such as hypoxia response, VEGF signaling, and vascular remodeling. Studies have identified miRNAs (e.g., miR-210, miR-146a, and miR-21) as potential biomarkers and therapeutic targets. Preclinical evidence supports miRNA-based therapies (e.g., miR-18a-5p and miR-181a), targeting HIF-1α and VEGFA to mitigate neovascularization, with nanoparticle delivery systems enhancing stability and specificity. These strategies, combined with anti-VEGF agents, show significant potential for improving ROP management. While promising, miRNA therapies require validation in clinical trials to ensure safety and efficacy. This review discusses the role of miRNAs in ROP, highlighting their relevance as diagnostic and therapeutic tools.

Indexed as

angiogenesisanti-VEGF therapyinflammationmiRNAsnon-invasive biomarkersoxygen-induced retinopathyretinal neovascularizationretinal vascularizationretinopathy of prematurityVEGF signaling

Identifiers

PMID40002813
PMCPMC11852721

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.